This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look: Discussing recent advancements and use of synthetic lethality based cancer therapeutics and areas for future development.
Ticker(s): IDYA, MRK, AZNWho's the expert?
- Board-certified oncologist practicing medicine at the Oncology Institute of Hope and Innovation.
- 25+ years in clinical practice, the majority spent serving as the Medical Directorfor Oncology/Hematology for Kaiser Permanente in San Diego.
- Transitioned to the diagnostic industry where he has been the Medical Director for Hematology / Oncology forQuest Diagnostics and the Chief Medical Officer for Agendia, and Signal Genetics, bothmolecular diagnostics companies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
